Expert medicinal chemist consults on drug discovery, preclinical development, intellectual property strategies for start-up biotechnology, pharmaceutical and diagnostic companies

Medicinal Chemist Expert for Drug Discovery and Preclinical Development (1208)

Independent Consultant, 2004-Present

Provide independent R&D (medicinal chemistry, drug discovery and preclinical development), business development and fundraising consulting services for established and start-up biotech, pharma and diagnostic companies.

Vice President, Research & Development, Managing Director, Molecular Imaging, (Subsidiary of Siemens), 2003-2004

Device, Software, Radiotracer and Diagnostic R&D. Led integrated medicinal chemistry, radiochemistry, physics, biology, probe discovery and development, microfluidics, hardware and software engineering functions.
President and Director for subsidiary, CTI Technologies, Inc.
Initiated development on new PET radiotracers for imaging Alzheimer’s disease and cancer; managed multiple device, software and probe projects.

President and Chief Scientific Officer, Ceretek, LLC, 2000-2003

Lead all R&D, Business Development and fundraising activities. Full P&L responsibilities.
Developed substantial intellectual property portfolio covering novel receptors, assays and lead compounds.
Established and implemented the Company strategy of drug discovery and development targeting Lipid G-Protein Coupled Receptors (L-GPCRs) to identify novel therapeutics for cancer, immune, cardiovascular, ophthalmic and CNS disorders.
Led team that identified first novel subtype selective Edg1, Edg2, Edg4 and Edg7 antagonists.

Vice President, Scientific Affairs, Questcor Pharmaceuticals, Inc., 1997-2000

Led Questcor’s antiinfective and cytoprotective preclinical research. Line management responsibility for biology, chemistry, informatics, and screening for the company.
Developed novel and successful antibacterial, antifungal and antiviral (Hepatitis C) programs certain of which are currently in preclinical or early clinical development.

Director of Chemistry, Synaptic Pharmaceutical Corp., 1991-1997

Directed the chemistry effort for successful projects including: alpha 1a antagonist project targeting Benign Prostatic Hyperplasia (BPH); alpha 1 and alpha 2 agonist projects for urinary incontinence, pain and glaucoma; novel NPY5 antagonists for treating obesity.

Senior Scientist, Medicinal Chemistry, Allergan, Inc., 1989-1990

Initiated and led the medicinal chemistry effort focusing on the discovery of novel alpha 2 agonists for the treatment of glaucoma.
Initiated the medicinal chemistry effort focusing on hypotensive lipids for the treatment of glaucoma.